Horizon Discovery Group plc Issue of Equity (5200V)
January 31 2017 - 2:00AM
UK Regulatory
TIDMHZD
RNS Number : 5200V
Horizon Discovery Group plc
31 January 2017
Horizon Discovery Group plc
Issue of Equity
Cambridge, UK, 31 January 2017: Horizon Discovery Group plc
(LSE: HZD) ("Horizon" or the "Company"), the world leader in the
application of gene editing technologies, today announces that,
further to the announcement made on 8 January 2015, the conditions
for the issue of additional new ordinary shares of 1p each in the
Company to former shareholders of Haplogen Genomics GmbH
("Haplogen") pursuant to a Sale and Purchase Agreement dated 7
January 2015 (the "Sale and Purchase Agreement") have been
satisfied. This represents the final consideration payable in
respect of the acquisition of Haplogen.
Horizon has approved the allotment and issue of 857,971 new
ordinary shares of 1p each in the Company (the "Second Earn-Out
Shares") to the former shareholders of Haplogen under the Sale and
Purchase Agreement, and an application has been made for the
admission to trading on AIM of the Second Earn Out Shares
("Admission"). Admission is expected to take place on or about 3
February 2017. The Second Earn Out Shares will rank pari passu in
all respects with Horizon's existing shares in issue.
Following Admission, the Company's enlarged issued share capital
will comprise 96,136,838 Ordinary Shares with one voting right per
share. No shares are held in Treasury. The total number of voting
rights in the Company is therefore 96,136,838. This figure of
96,136,838 ordinary shares may be used by shareholders in the
Company as the denominator for the calculations by which they will
determine if they are required to notify their interest in, or a
change in their interest in, the share capital of the Company under
the FCA's Disclosure and Transparency Rules.
ENDS
Notes for Editors:
For further information from Horizon Discovery Group plc, please
contact:
Horizon Discovery Group plc
Darrin Disley, Chief Executive Officer
Richard Vellacott, Chief Financial Officer
Chris Claxton, VP Investor Relations
Tel: +44 (0) 1223 655 580
Consilium Strategic Communications (Financial Media and Investor
Relations)
Mary-Jane Elliott / Susan Stuart / Matthew Neal / Melissa
Gardiner
Tel: +44 (0) 20 3709 5701
Email: horizon@consilium-comms.com
Numis Securities Limited (Joint Broker and NOMAD)
Michael Meade / Freddie Barnfield
Tel: +44 (0) 207 260 1000
RBC Capital Markets (Joint Broker)
Paul Tomasic / Marcus Jackson
Tel: +44 (0) 20 7653 4000
About Horizon Discovery Group plc www.horizondiscovery.com/
Horizon Discovery Group plc (LSE: HZD) ("Horizon"), is a
world-leading gene editing company that designs and engineers
genetically-modified cells and then applies them in research and
clinical applications that advance human health.
Horizon's core capabilities are built around its proprietary
translational genomics platform, a highly precise and flexible
suite of gene editing tools (rAAV, ZFN and CRISPR) able to alter
almost any gene sequence in human or mammalian cell-lines.
Horizon offers over 23,000 catalogue products and related
research services, almost all of which are based on the generation
and application of cell and in vivo models that accurately
recapitulate the disease-causing genetic anomalies found in
diseases like cancer. Horizon's commercial offering has been
adopted by c1,600 unique research organisations in over 50
countries as well as in the Group's own R&D pipeline to support
a greater understanding of the genetic drivers of disease and the
development of molecular, cell and gene therapies that can be
prescribed on a personalised basis.
Horizon is headquartered in Cambridge, UK, and is listed on the
London Stock Exchange's AIM market under the ticker "HZD".
This information is provided by RNS
The company news service from the London Stock Exchange
END
IOELLFLTLEIIVID
(END) Dow Jones Newswires
January 31, 2017 02:00 ET (07:00 GMT)
Horizon Discovery (LSE:HZD)
Historical Stock Chart
From Apr 2024 to May 2024
Horizon Discovery (LSE:HZD)
Historical Stock Chart
From May 2023 to May 2024